You are here

Injectable Foam to Staunch Bleeding is Breakthrough Therapy

Lifesaving Life Foam for Battlefield, Terrorist Attacks, Trauma

Life Foam™, an expanding, internal-use injectable hemostat, designed by gel-e Inc., has received a breakthrough status designation from the FDA.

Life Foam provides rapid, temporary control of bleeding from non-compressible abdominal wounds that do not lend themselves to tourniquet application during trauma and battlefield conditions. The product is designed to save the lives of those injured in battle, or who are victims of traumatic accidents or terrorist attacks.

Trauma from accidents is the third leading cause of death in the U.S. after heart disease and cancer. Approximately 85% of all hemorrhage-related deaths arise from non-compressible internal bleeding––intracavitary (e.g., abdominal) bleeding that is not accessible to direct pressure and cannot be controlled by typical methods such as gauze or a tourniquet.

When it is delivered into the abdominal cavity, Life Foam expands dramatically, seeking out the bleeding source in the patient for quick and efficient stabilization. This enables the injured person to be safely transported to a trained trauma surgeon, who can repair the damage in a controlled surgical environment.

The foam is currently in preclinical development for treating patients who have been injured in battlefield conditions or where life-threatening internal bleeding occurs in a location away from immediate urgent care.

Source: BioSpace, June 18, 2019

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Acasti reports disappointing results for a second Omega-3-based drug
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks